

CHINA MEDICAL (INTERNATIONAL) GROUP LIMITED
(Company Registration No. 200505118M)
(the “**Company**”)

PROPOSED CORPORATE EXERCISES – RECEIPT OF LISTING AND QUOTATION NOTICE

1. INTRODUCTION

1.1 The Board of Directors (“**Directors**”) of China Medical (International) Group Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) refers to the announcement made by the Company on 26 August 2018 (“**Previous Announcement**”) in relation to the Proposed Corporate Exercises.

1.2 Unless otherwise defined, all capitalised terms used herein shall bear the same meanings as ascribed to them in the Previous Announcement. Any reference to the time of day and date herein shall be a reference to Singapore time and date, respectively.

2. LISTING AND QUOTATION NOTICE

2.1 The Directors wish to announce that the Company’s Sponsor (as defined below) has, on 30 November 2018, obtained the listing and quotation notice (the “**LQN**”) from the SGX-ST in respect of the listing and quotation of:

2.1.1 4,406,389,473 Consolidated Shares;

2.1.2 up to 3,214,285,714 Conversion Shares;

2.1.3 2,857,142,857 Subscription Shares;

2.1.4 142,857,143 Introducer Shares; and

2.1.5 up to 952,380,952 Warrant Shares,

on the Catalist Board of the SGX-ST, subject to the following:

2.1.6 compliance with the listing requirements of the SGX-ST; and

2.1.7 shareholders’ approval for the Proposed Deferred Liability Conversion, Proposed Share Subscription, Proposed Warrants Issue and Proposed Introducer Shares Issue to be obtained at an extraordinary general meeting to be convened.

2.2 The LQN also stipulates that the Conversion Shares, Subscription Shares and Introducer Shares have to be placed out within seven (7) market days from the approval from shareholders for the Proposed Deferred Liability Conversion, Proposed Share Subscription, Proposed Warrants Issue and Proposed Introducer Shares Issue.

2.3 Please note that the LQN is not an indication of the merits of any of the Conversion Shares, Proposed Deferred Liability Conversion, Subscription Shares, Proposed Share Subscription, Introducer Shares, Proposed Introducer Share Issue, Warrant Shares, Warrants, Proposed Warrants Issue, the Company, its subsidiaries and their securities.

2.4 A circular to shareholders setting out, *inter alia*, the Proposed Corporate Exercises together with a notice convening the extraordinary general meeting to seek shareholders’ approval for the Proposed Corporate Exercises will be despatched to shareholders in due course.

3. RESPONSIBILITY STATEMENT

The Directors collectively and individually accept full responsibility for the accuracy of the information given in this announcement and confirm after making all reasonable enquiries, that to the best of their knowledge and belief, this announcement constitutes full and true disclosure of all material facts about the Proposed Corporate Exercises, the Company and its subsidiaries, and the Directors are not aware of any facts the omission of which would make any statement in this announcement misleading. Where information in the announcement has been extracted from published or otherwise publicly available sources or obtained from a named source, the sole responsibility of the Directors has been to ensure that such information has been accurately and correctly extracted from those sources and/or reproduced in the announcement in its proper form and context.

In the meantime, the Directors wish to advise shareholders of the Company and investors to exercise caution when dealing in the shares of the Company (“Shares”) and to refrain from taking any action in relation to their Shares which may be prejudicial to their interests. Persons who are in doubt as to the action they should take should consult their stockbrokers, bank managers, solicitors, accountants, tax advisers or other professional advisers immediately. The Company will make further announcements as appropriate with regard to the above matters.

BY ORDER OF THE BOARD

Hano Maeloa

30 November 2018

This Announcement has been prepared by the Company and its contents have been reviewed by the Company’s sponsor, PrimePartners Corporate Finance Pte. Ltd. (the “Sponsor”) for compliance with the Singapore Exchange Securities Trading Limited (the “SGX-ST”) Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this Announcement.

This Announcement has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this Announcement, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this Announcement.

The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship (Mailing Address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and E-mail: sponsorship@ppcf.com.sg).